Last reviewed · How we verify

NCT05475574: Ger-SP

Impact of Discontinuing Contact Precautions for Extended-spectrum β-lactamase Enterobacteriaceae in a Geriatric Unit

Recruiting now NA Last updated 27 April 2025
What this trial tests

NA trial testing Discontinuation of contact precautions for ESBLE in Infection, Hospital in 954 participants. Currently enrolling.

Timeline
7 March 2023
Primary endpoint
7 September 2029
21 September 2029

Quick facts

Lead sponsorCentre Hospitalier Régional Metz-Thionville
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingtriple
Primary purposeprevention
Enrollment954
Start date7 March 2023
Primary completion7 September 2029
Estimated completion21 September 2029
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre Hospitalier Régional Metz-Thionville

Who can join

65 and older, any sex, with Infection, Hospital. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an interventional multicenter prospective noninferiority non-randomized double-blind controlled before and after study. The aim of this study is to demonstrate that standard precautions alone are not inferior to contact precautions by comparing the incidence density of extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae acquired in geriatric units before and after discontinuing contact precautions.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Infection, Hospital

Currently open trials in the same condition.

Other Centre Hospitalier Régional Metz-Thionville trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05475574.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing